{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-206176","form_type":"8-K","ticker":null,"cik":"0001576263","company_name":"Mirati Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.402131+00:00","generated_at":"2026-06-12T01:56:17.494439+00:00","sec_items":["2.02","5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirati CEO David Meek departs; Charles Baum interim CEO; Q2 net loss $176.9M, KRAZATI rev $13.4M","bullets":["CEO David Meek resigned Aug 7, 2023; founder Charles Baum named interim CEO; Meek remains consultant through Oct 15.","Q2 net loss $176.9M ($3.04/sh); KRAZATI revenue $13.4M; cash $779.4M; FY23 net cash burn guidance $560-580M.","Plans Phase 3 adagrasib + pembro in 1L NSCLC TPS≥50% by year-end; CHMP issued negative opinion on conditional MAA.","MRTX1719 initial data show favorable safety and early activity in MTAP-deleted cancers; Phase 2 planned H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-206176","json":"https://secwatch.observer/filing/0001193125-23-206176.json","markdown":"https://secwatch.observer/filing/0001193125-23-206176.md","text":"https://secwatch.observer/filing/0001193125-23-206176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/d499867d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:56:17.494439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49890760a9fa6dc6811a616fd5419556154ac2ad","claim":"Mirati Therapeutics, Inc. reported financial results for second quarter 2023.","evidence_excerpt":"On August 8, 2023, Mirati Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f465c5bdeb","claim":"David Meek resigned as Chief Executive Officer at Mirati Therapeutics, Inc..","evidence_excerpt":"On August 7, 2023 (the “Meek Separation Date”), David Meek resigned as a member of the Company’s board of directors and as the Company’s Chief Executive Officer and principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fe6005a301","claim":"Charles M. Baum was appointed as Interim Chief Executive Officer at Mirati Therapeutics, Inc..","evidence_excerpt":"The Company’s board of directors has, effective as of the Meek Separation Date, appointed Charles M. Baum, M.D., Ph.D., in addition to his other titles, as Interim Chief Executive Officer of the Company and as the Company’s principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}